Long-term gastrointestinal tolerance of NUTRIOSE®FB in healthy men
Autor: | Wilrike Pasman, M.-H. Saniez, Daniel Wils, A. F. M. Kardinaal |
---|---|
Přispěvatelé: | TNO Kwaliteit van Leven TNO Voeding |
Rok vydání: | 2006 |
Předmět: |
Questionnaires
Male Hunger Macronutrient Medicine (miscellaneous) Gastroenterology law.invention Feces Hydrogen breath test Randomized controlled trial Quality of life Absence of side effects Food intake law Controlled clinical trial Surveys and Questionnaires Enzyme activity Hematological parameters Food science Drug tolerability Nutrition and Dietetics medicine.diagnostic_test Feces analysis Short chain fatty acid Lactic acid Double blind procedure Sitosterol Dietary fiber Adaptation Physiological Nutriose fb Clinical trial Diarrhea Cholesterol Cholesterol blood level Body mass Breath Tests Health Food composition medicine.symptom Adult medicine.medical_specialty Beta glucosidase Diet therapy Fermentation technique Diet supplementation Placebo Colon flora Maltodextrin Double-Blind Method Polysaccharides Gastrointestinal symptom Internal medicine Dextrins medicine Humans Biomedical research Alpha glucosidase Drug excretion Adaptation Coprosterol Dose-Response Relationship Drug business.industry Probiotics Body Weight Body weight Satiety Glucose Food preference Fermentation Quality of Life Glucidex Habituation Caloric intake Energy Intake business PH measurement |
Zdroj: | European Journal of Clinical Nutrition, 8, 60, 1024-1034 |
ISSN: | 1476-5640 0954-3007 |
DOI: | 10.1038/sj.ejcn.1602418 |
Popis: | Objective: To determine the gastrointestinal (GI) tolerance of NUTRIOSE®FB in men. Design: A randomized, placebo-contro lled, parallel, double-blind study. Setting: The metabolic ward of TNO Quality of Life. Subjects: Forty-eight subjects started the study: 16 men participated in one of the three treatments. Subjects consumed either 22.5 g of pure maltodextrin (Glucidex®6), or 30 or 45 g of the dextrin NUTRIOSE®FB daily for 4-5 weeks. Forty-three subjects completed the study (age: 34.7±8.2 years; BMI 24.9±3.3 kg m2). Measurements: Tolerance of NUTRIOSE®FB was examined with a GI complaints questionnaire; effectiveness on colonic flora was examined by faecal analysis; fermentation by breath hydrogen excretion measurement. Furthermore, the effect on body weight (BW), energy intake and blood parameters were examined in the study. Results: Both doses of NUTRIOSE®FB were very well tolerated and GI complaints hardly differed from the placebo treatment. No diarrhoea was reported due to NUTRIOSE®FB supplementation. In the course of the study, some habituation and adaptation of GI symptoms were found. Fermentation and faecal characteristics (pH and enzyme activity) were significantly positively affected with NUTRIOSE®FB treatment. Body weight in both NUTRIOSE®FB groups remained stable over time, although the placebo-treated group showed a small increase in BW (Δday35-1 0.8±1.0 kg) (P=0.07). However, total food intake and macronutrient composition of the diet remained the same throughout the study. No significant differences were found between the three treatment groups in hunger and satiety scores and food preferences. Conclusions: Long-term supplementation of 30 or 45 g of the dextrin NUTRIOSE®FB per day was well tolerated, and may act as a pre-biotic supplement. © 2006 Nature Publishing Group. All rights reserved. |
Databáze: | OpenAIRE |
Externí odkaz: |